Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: Data from the CASTLE study
AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, Volume 22, No. 6, Year 2010
Notification
URL copied to clipboard!
Description
Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naive HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: Improvement (≥2-point positive change from baseline), No change (≥2-point change), or Worsening (<2-point negative change). Data were collected on GI adverse events (AEs) and use of GI medications. Of the 599 patients with IBS-QoL-evaluable data through week 24, fewer patients in the ATV/RTV group than in the LPV/RTV group experienced grade 2-4 treatment-related GI AEs including diarrhea (3% versus 10%), nausea (5% versus 7%), and vomiting (<1% on both arms). Nearly three times as many patients receiving LPV/RTV used GI medications. ATV/RTV was associated with an increase in overall IBS-QoL scores and more patients receiving ATV/RTV than LPV/RTV experienced improvement in IBS-QoL through week 24. In contrast to LPV/RTV, ATV/RTV treatment was associated with earlier and more positive improvements in QoL scores across CD4 sub-groups. Differences in the health-related QoL profile between ATV/RTV and LPV/RTV may be important when selecting PI-based antiretroviral regimens. © 2010 Taylor & Francis.
Authors & Co-Authors
Malan, Niel
South Africa, Port Elizabeth
Triple M Research, Port Elizabeth
Su, Jun
United States, New York
Bristol-myers Squibb
Mancini, Marco
United States, New York
Bristol-myers Squibb
Yang, Rong
United States, New York
Bristol-myers Squibb
Wirtz, Victoria
United States, New York
Bristol-myers Squibb
Absalon, Judith
United States, New York
Bristol-myers Squibb
McGrath, Donnie
United States, New York
Bristol-myers Squibb
Statistics
Citations: 20
Authors: 7
Affiliations: 2
Identifiers
Doi:
10.1080/09540120903334641
ISSN:
09540121
e-ISSN:
13600451
Research Areas
Disability
Health System And Policy
Infectious Diseases